

Revised Draft Agenda
Biocides Working Group Meeting I-2023
13 – 24 March 2023

WG-I-2023 meetings are held as remote meetings via WebEx

The time is indicated in Helsinki time.

Monday 13 March	10:30-18:00	APCP WG
Tuesday 14 March	10:30-18:00	APCP WG
Wednesday 15 March	10:30-18:00	APCP WG (reserve day)
Tuesday 14 March	10:00-18:00	TOX WG
Wednesday 15 March	10:00-18:00	TOX WG
Thursday 16 March	10:00-18:00	TOX WG
Tuesday 21 March	10:00-18:00	TOX WG (reserve day)
Tuesday 14 March	10:00-17:00	EFF WG
Thursday 16 March	10:30-18:00	EFF WG
Tuesday 21 March	10:00-17:00	EFF WG
Thursday 23 March	10:30-18:00	EFF WG (reserve day)
Tuesday 21 March	10:00-18:00	ENV WG
Wednesday 22 March	10:00-18:00	ENV WG (reserve day)
Thursday 23 March	10:00-18:00	ENV WG
Friday 24 March	10:00-18:00	ENV WG

Analytical methods and physico-chemical properties Working Group Chair: Andreas Uphoff		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		
<i>For agreement</i>		
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement on the minutes of WG IV 2022		
<i>For agreement</i>		
Item 6 - Active Substances		eCA
6.1.	Garlic extract PT19 Meeting document: WGI2023_APCP_6-1 <div style="text-align: right;"><i>For agreement</i></div>	AT
6.2.	Pentapotassium bis(peroxymonosulphate) bis(sulphate) PT 2, 3, 4, 5 Meeting document: WGI2023_APCP_6-2 <div style="text-align: right;"><i>For agreement</i></div>	SI
6.3	Early WG discussion - Alphachloralose (closed session) PT 14 Meeting document: WGI2023_APCP_6-3 <div style="text-align: right;"><i>For discussion</i></div>	PL
6.4	Early WG discussion – TMAD identification Meeting document: WGI2023_APCP_6-4 <div style="text-align: right;"><i>For discussion</i></div>	ES
Item 7 – Union Authorisations		eCA
7.1	UA for a product family containing L-(+)-lactic acid PT3 Meeting document: WGI2023_APCP_7-1 <div style="text-align: right;"><i>For agreement</i></div>	NL
7.2	UA for a product containing Hydrogen peroxide and L-(+)-lactic acid PT2, PT3, PT4 Meeting document: WGI2023_APCP_7-2 <div style="text-align: right;"><i>For agreement</i></div>	FR

Item 8 - Technical and guidance related issues		Presenter
8.1	Update of the APCP TAB (closed session) Meeting document: WGI2023_APCP_8-1 <i>For agreement</i>	NL
8.2	Exchange on problems during evaluation (closed session) Meeting document: WGI2023_APCP_8-2 <i>For discussion</i>	ECHA
8.3	Waiving of oxidising properties for simple oxides (closed session) Meeting document: WGI2023_APCP_8-3 <i>For discussion</i>	NL/FI
8.4	Read-across possibilities for SADT (closed session) Meeting document: WGI2023_APCP_8-4 <i>For discussion</i>	DE/NL
8.5	Global composition for in situ generated active substance (closed session) Meeting document: WGI2023_APCP_8-5 <i>For discussion</i>	AT/FI
Item 9 - AOB		

Human Health Working Group		
Chair: Antero Airaksinen		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		
<i>For agreement</i>		
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement on the minutes of WG-IV-2022		
<i>For agreement</i>		
Item 6 - Active Substances		eCA
6.1.	Garlic extract PT 19 Meeting document: WGI2023_TOX_6-1 <div style="text-align: right;"><i>For agreement</i></div>	AT
6.2.	Pentapotassium bis(peroxymonosulphate) bis(sulphate) PT 2, 3, 4, 5 Meeting document: WGI2023_TOX_6-2 <div style="text-align: right;"><i>For agreement</i></div>	SI
6.3	Early WG discussion - Alphachloralose PT 14 Meeting document: WGI2023_TOX_6-3 <div style="text-align: right;"><i>For discussion</i></div>	PL
Item 7 - Union Authorisations		eCA
7.1	UA for a product family containing L-(+)-lactic acid PT 3 Meeting document: WGI2023_TOX_7-1 <div style="text-align: right;"><i>For agreement</i></div>	NL
7.2	UA for a product containing Hydrogen peroxide and L-(+)-lactic acid PT 2, 3, 4 Meeting document: WGI2023_TOX_7-2 <div style="text-align: right;"><i>For agreement</i></div>	FR

Item 8 – Article 75(1)(g) requests		Presenter
8.1	Article 75(1)(g) mandate: Comparative assessment of anticoagulant rodenticides Meeting document: WGI2023_TOX_8-1 <i>For discussion</i>	SECR
Item 9 – Technical and guidance related items		Presenter
9.1	CLP revision Meeting document: WGI2023_TOX_9-1 <i>For information</i>	SECR
9.2	ARTFood: ADI and ARfD derivation for biocidal active substances Meeting document: WGI2023_TOX_9-2 <i>For discussion</i>	SECR
9.3	ARTFood: Transfer coefficient for dislodgeable residues and systemic availability Meeting document: WGI2023_TOX_9-3 <i>For agreement</i>	DE
9.4	ARTFood: Assessment of residue transfer to food from PT 3 and 4 uses for biocidal substances with MRLs Meeting document: WGI2023_TOX_9-4 <i>For agreement</i>	FR
Item 10– AoB		Presenter
10.1	Other information Meeting document: WGI2023_TOX_10-1 <i>For discussion</i>	SECR

Environment Working Group		
Chair: Sander van der Linden		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		
<i>For agreement</i>		
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement on the minutes of WG-IV-2022		
<i>For agreement</i>		
Item 6 - Active Substances		eCA
6.1.	Garlic extract PT19 Meeting document: WGI2023_ENV_6-1 <div style="text-align: right;"><i>For agreement</i></div>	AT
6.2.	Pentapotassium bis(peroxymonosulphate) bis(sulphate) PT 2, 3, 4, 5 Meeting document: WGI2023_ENV_6-2 <div style="text-align: right;"><i>For agreement</i></div>	SI
6.3	Early WG discussion - Alphachloralose PT 14 Meeting document: WGI2023_ENV_6-3 <div style="text-align: right;"><i>For discussion</i></div>	PL
6.4	Early WG discussion - dissipation of OIT in two open recirculating liquid cooling systems PT11 Meeting document: WGI2023_ENV_6-4 <div style="text-align: right;"><i>For discussion</i></div>	FR
6.5	Early WG discussion: refinement of environmental risk assessment of copper powder PT21 Meeting document: WGI2023_ENV_6-5 <div style="text-align: right;"><i>For discussion</i></div>	FR

Item 7 - Union Authorisations		eCA
7.1	UA for a product family containing L-(+)-lactic acid PT3 Meeting document: WGI2023_ENV_7-1 <i>For agreement</i>	NL
7.2	UA for a product containing Hydrogen peroxide and L-(+)-lactic acid PT2, PT3, PT4 Meeting document: WGI2023_ENV_7-2 <i>For agreement</i>	FR
Item 8 – Article 75(1)(g) requests		Presenter
8.1	Article 75(1)(g) mandate: Comparative assessment of anticoagulant rodenticides Meeting document: WGI2023_ENV_8-1 <i>For discussion</i>	ECHA
8.2	Article 75(1)(g) mandate: Re-assessing the risk on the environment (soil compartment) posed by ADBAC/BKC from use in biocidal products of PT2 Meeting document: WGI2023_ENV_8-2 <i>For agreement</i>	ECHA
Item 9– Mutual recognition		Presenter
9.1	COM request for ECHA opinion pursuant to Articles 36(2) and 38 of the BPR for a PT 5 biocidal product family intended for disinfection of drinking water for animals (closed session) Meeting document: WGI2023_ENV_9-1 <i>For agreement</i>	ECHA

Item 10 – Technical and guidance related items		Presenter
10.1	Worst case and best case concentrations in a product family Meeting document: WGI2023_ENV_10-1 <i>For discussion</i>	ECHA
10.2	Pollinator guidance update Meeting document: WGI2023_ENV_10-2 <i>For information</i>	ECHA
10.3	Risk assessment of DBPs Meeting document: WGI2023_ENV_10-3 <i>For discussion/information</i>	FR
10.4	CLP revision Meeting document: WGI2023_ENV_10-4 <i>For information</i>	ECHA
Item 11– AoB		Presenter
11.1	Other information Meeting document: WGI2023_ENV_11-1 <i>For discussion</i>	ECHA

Efficacy Working Group		
Chair: Kasia Szymankiewicz		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		
<i>For agreement</i>		
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement on the minutes of WG IV 2022		
<i>For agreement</i>		
Item 6 - Active Substances		eCA
6.1	Garlic extract PT19 Meeting document: WGI2023_EFF_6-1 <div style="text-align: right;"><i>For agreement</i></div>	AT
6.2	Pentapotassium bis(peroxymonosulphate) bis(sulphate) PT2 Meeting document: WGI2023_EFF_6-2 <div style="text-align: right;"><i>For agreement</i></div>	SI
Item 7 - Union Authorisations		eCA
7.1	UA for a product family containing L-(+)-lactic acid PT3 Meeting document: WGI2023_EFF_7-1 <div style="text-align: right;"><i>For agreement</i></div>	NL
7.2	UA for a product containing Hydrogen peroxide and L-(+)-lactic acid PT2, 3, 4 Meeting document: WGI2023_EFF_7-2 <div style="text-align: right;"><i>For agreement</i></div>	FR
7.3	Early WG discussion on UA-APP containing C(M)IT/MIT PT6, 11, 12, 13 Meeting document: WGI2023_EFF_7-3 <div style="text-align: right;"><i>For agreement</i></div>	NL
7.4	Early WG discussion on UA-APPs containing active chlorine generated from sodium chloride by electrolysis PT2, 4, 5 Meeting document: WGI2023_EFF_7-4 <div style="text-align: right;"><i>For agreement</i></div>	NL

7.5	Early WG discussion on UA-APPs containing active chlorine generated from sodium chloride by electrolysis PT 2, 4, 5 Meeting document: WGI2023_EFF_7-5 <i>For agreement</i>	NL
7.6	Early WG discussion on UA-APP containing active chlorine released from calcium hypochlorite PT2 Meeting document: WGI2023_EFF_7-6 <i>For agreement</i>	AT
7.7	Early WG discussion on UA-APP containing active chlorine released from calcium hypochlorite PT2, 4, 5 Meeting document: WGI2023_EFF_7-7 <i>For agreement</i>	DE
Item 8 – Mutual recognition		Presenter
8.1	COM request for ECHA opinion pursuant to Articles 36(2) and 38 of the BPR (closed session) Meeting document: WGI2023_EFF_8-1 <i>For agreement</i>	ECHA
Item 9 – Technical and guidance related issues		Presenter
9.1	Antimicrobial resistance - draft guidance Meeting document: WGI2023_EFF_9-1 <i>For discussion</i>	FR/DE
9.2	PT19 topical repellents for human skin against mosquitoes – simulated-use test required landing rate Meeting document: WGI2023_EFF_9-2 <i>For discussion</i>	DE
9.3	TAB proposal - how to determine the duration of efficacy of the disinfection bath Meeting document: WGI2023_EFF_9-3 <i>For discussion</i>	NL
9.4	Guidance needs and its prioritisation Meeting document: WGI2023_EFF_9-4 <i>For discussion</i>	ECHA
Item 10 – AOB		Presenter
10.1	Other information Meeting document: WGI2023_EFF_10-1 <i>For information</i>	ECHA